1-20 of 90
Hui Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer

Yanchao Yu, Xincheng Gao, Huayuan Zhao, Jiayin Sun, Miao Wang, Xing Xiong, Junping Li, Chao Huang, Hui Zhang, Guosong Jiang, Xingyuan Xiao
Journal: Cancer Research
Cancer Res (2025)
https://doi.org/10.1158/0008-5472.CAN-24-3217
Published: 24 March 2025
View articletitled, A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer
Open the PDF for A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A009: Mutant KRAS in Circulating Tumor DNA Assessed by Digit Droplet PCR as a Biomarker in Pancreatic Cancer in Patients Treated with Neoadjuvant Chemotherapy

Dominic Vitello, Dhavan Shah, Amy Wells, Larissa Masnyk, Madison Cox, Lauren Janczewski, John Abad, Kevin Dawravoo, Arlene D'Souza, Grace Suh, Robert Bayer, Massimo Cristofanilli, David Bentrem, Yingzhe Liu, Hui Zhang, Lucas Santana-Santos, Lawrence Jennings, Qiang Zhang, Akhil Chawla
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement_2): A009.
https://doi.org/10.1158/1538-7445.PANCREATIC24-A009
Published: 15 September 2024
View articletitled, Abstract A009: Mutant KRAS in Circulating Tumor DNA Assessed by Digit Droplet PCR as a Biomarker in Pancreatic Cancer in Patients Treated with Neoadjuvant Chemotherapy
Journal Articles

Abstract PO3-19-07: AC699-001, a first in human Phase 1 trial utilizing a novel estrogen receptor chimeric degrader in patients with advanced or metastatic breast cancer

Manish R Patel, Rachel Layman, Joy Nolte Fong, Hui Zhang, Su Kim, Erika Hamilton
Journal: Cancer Research
Cancer Res (2024) 84 (9_Supplement): PO3-19-07.
https://doi.org/10.1158/1538-7445.SABCS23-PO3-19-07
Published: 02 May 2024
View articletitled, Abstract PO3-19-07: AC699-001, a first in human Phase 1 trial utilizing a novel estrogen receptor chimeric degrader in patients with advanced or metastatic breast cancer
Journal Articles

Abstract 7354: Proteogenomic and metabolomic characterization of acute myeloid leukemia

Alec Chu, Yi Hsiao, Yamei Deng, Chenwei Wang, Jennifer Kyle, Yongchao Dou, James C. Pino, Camilo Posso, Leanne Henry, Lijun Chen, Ginny Xiaohe Li, Tung-Shing Mamie Lih, Yifat Geffen, Fengchao Yu, Li Ding, Gil Omenn, Chandan Kumar, Saravana M. Dhanasekaran, Elie Traer, Jeffrey W. Tyner, Hui Zhang, Tao Liu, Sara Gosline, Bing Zhang, Arul Chinnaiyan, Alexey I. Nesvizhskii, Marcin Cieslik, The CPTAC Consortium
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7354.
https://doi.org/10.1158/1538-7445.AM2024-7354
Published: 22 March 2024
View articletitled, Abstract 7354: Proteogenomic and metabolomic characterization of acute myeloid leukemia
Journal Articles

Abstract 5097: Effectiveness and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: A multicenter, retrospective real-world study in China

Hui Zhang, Minghua Shao, Binbin Tan, Yin Fu, Yuan, Hailei Chen
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5097.
https://doi.org/10.1158/1538-7445.AM2024-5097
Published: 22 March 2024
View articletitled, Abstract 5097: Effectiveness and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: A multicenter, retrospective real-world study in China
Journal Articles

Abstract 1890: HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models

Yan Xu, Junqing Liang, Shuwen Jiang, Haibin Yang, Hui Zhang, Fangfang Mao, Jiahuan Zhu, Jianlin He, Na Yang, Jian Wang, WeiHan Zhang, Yongxin Ren, Weiguo Su
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1890.
https://doi.org/10.1158/1538-7445.AM2024-1890
Published: 22 March 2024
View articletitled, Abstract 1890: HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models
Journal Articles

Abstract 3955: A proteogenomic study of high-grade glioma among adolescents and young adults

Nicole Tignor, Mateusz P. Koptyra, Shrabanti Chowdhury, Weiping Ma, Jo Lynne Rokita, Marina Gritsenko, Xiaoyu Song, Giacomo B. Marino, Eden Z. Deng, Francesca Petralia, Azra Krek, Dmitry Rykunov, Felipe da Veiga Leprevost, Noshad Hosseini, Komal S. Rathi, Yingwei Hu, Simona Migliozzi, Tomer Yaron, Weijia Fu, Bo Zhang, Yuankun Zhu, Miguel A. Brown, Jeffrey R. Whiteaker, Clinical Proteomics Tumor Analysis Consortium (CPTAC), Children’s Brain Tumor Network (CBTN), Mehdi Mesri, Ana I. Robles, Karin Rodland, Lewis C. Cantley, Antonio Iavarone, Kenneth Aldape, Marcin Cieślik, Alexey I. Nesvizhskii, Joseph E. Ippolito, Joshua B. Rubin, Amanda G. Paulovich, Hui Zhang, Avi Ma'ayan, Tao Liu, Phillip B. Storm, Adam C. Resnick, Brian R. Rood, Pei Wang
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3955.
https://doi.org/10.1158/1538-7445.AM2024-3955
Published: 22 March 2024
View articletitled, Abstract 3955: A proteogenomic study of high-grade glioma among adolescents and young adults
Journal Articles

Abstract 1661: Preclinical characterization of HMPL-295, a potent and selective ERK 1/2 inhibitor

Jia Hu, Jun Ni, Yuanzhi Lv, Wenjun Li, Hui Zhang, Xin Li, Ying Yu, Zeyu Zhong, Jian Wang, Yang Sai, Weiguo Qing, Yongxin Ren, Michael Shi, Weiguo Su
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1661.
https://doi.org/10.1158/1538-7445.AM2024-1661
Published: 22 March 2024
View articletitled, Abstract 1661: Preclinical characterization of HMPL-295, a potent and selective ERK 1/2 inhibitor
Journal Articles

Abstract 6915: Integrated proteogenomic analysis for the NCI patient-derived cancer model repository

Peter I. Wu, Li Chen, Yuri Kotliarov, Jianwen Fang, Yingdong Zhao, Yvonne Evrard, Lijun Chen, Shahanawaz Jiwani, Biswajit Das, Chris A. Karlovich, Hui Zhang, Lisa McShane, Melinda G. Hollingshead, Mickey Williams, James H. Doroshow
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6915.
https://doi.org/10.1158/1538-7445.AM2024-6915
Published: 22 March 2024
View articletitled, Abstract 6915: Integrated proteogenomic analysis for the NCI patient-derived cancer model repository
Journal Articles

Abstract 5612: MRE11 function in DNA damage response is regulated by SIRT2 deacetylation

Mark Essien, Fatmata Sesay, Hui Zhang, Andrew Jung, David Yu
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5612.
https://doi.org/10.1158/1538-7445.AM2024-5612
Published: 22 March 2024
View articletitled, Abstract 5612: MRE11 function in DNA damage response is regulated by SIRT2 deacetylation
Journal Articles

Abstract 2339: GPNotebook: A toolkit for identifying cancer-related glycosylation alterations in glycoproteomic analysis

Hui Zhang, Trung Hoang, Yingwei Hu
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 2339.
https://doi.org/10.1158/1538-7445.AM2024-2339
Published: 22 March 2024
View articletitled, Abstract 2339: GPNotebook: A toolkit for identifying cancer-related glycosylation alterations in glycoproteomic analysis
Journal Articles

Hypoxic Bone Marrow Stromal Cells Secrete miR-140–5p and miR-28–3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma

Hui Zhang, Zhimin Du, Chenggong Tu, Xinyan Zhou, Eline Menu, Jinheng Wang
Journal: Cancer Research
Cancer Res (2024) 84 (1): 39–55.
https://doi.org/10.1158/0008-5472.CAN-23-0189
Published: 02 January 2024
View articletitled, Hypoxic Bone Marrow Stromal Cells Secrete miR-140–5p and miR-28–3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma
Open the PDF for Hypoxic Bone Marrow Stromal Cells Secrete miR-140–5p and miR-28–3p That Target SPRED1 to Confer Drug Resistance in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

Yige Wu, Siqi Chen, Xiaolu Yang, Kazuhito Sato, Preet Lal, Yuefan Wang, Andrew T. Shinkle, Michael C. Wendl, Tina M. Primeau, Yanyan Zhao, Alanna Gould, Hua Sun, Jacqueline L. Mudd, Jeremy Hoog, R. Jay Mashl, Matthew A. Wyczalkowski, Chia-Kuei Mo, Ruiyang Liu, John M. Herndon, Sherri R. Davies, Di Liu, Xi Ding, Yvonne A. Evrard, Bryan E. Welm, David Lum, Mei Yee Koh, Alana L. Welm, Jeffrey H. Chuang, Jeffrey A. Moscow, Funda Meric-Bernstam, Ramaswamy Govindan, Shunqiang Li, James Hsieh, Ryan C. Fields, Kian-Huat Lim, Cynthia X. Ma, Hui Zhang, Li Ding, Feng Chen
Journal: Cancer Research
Cancer Res (2023) 83 (24): 4161–4178.
https://doi.org/10.1158/0008-5472.CAN-23-0604
Published: 15 December 2023
View articletitled, Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma
Open the PDF for Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract 3127: Comprehensive proteogenomic characterization of rare kidney tumors

Ginny Xiaohe Li, Yi Hsiao, Lijun Chen, Rahul Mannan, Yuping Zhang, Francesca Petralia, Hanbyul Cho, Noshad Hosseini, Anna Calinawan, Yize Li, Shankara Anand, Aniket Dagar, Yifat Geffen, Felipe V. Leprevost, Anne Le, Sean Ponce, Michael Schnaubelt, Nataly Naser Al Deen, Wagma Caravan, Andrew Houston, Chandan Kumar-Sinha, Xiaoming Wang, Seema Chugh, Gilbert S. Omenn, Daniel W. Chan, Christopher Ricketts, Rohit Mehra, Arul Chinnaiyan, Li Ding, Marcin Cieslik, Hui Zhang, Saravana M. Dhanasekaran, Alexey I. Nesvizhskii
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3127.
https://doi.org/10.1158/1538-7445.AM2023-3127
Published: 04 April 2023
View articletitled, Abstract 3127: Comprehensive proteogenomic characterization of rare kidney tumors
Journal Articles

Abstract OT3-23-01: VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors

Manish R Patel, Dejan Juric, Brian S Henick, Kathleen N Moore, Doreen Do, Joshua Chapman, Hui Zhang, Maria Roche, Kate J Newberry, Mikael Rinne, Timothy A Yap
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): OT3-23-01.
https://doi.org/10.1158/1538-7445.SABCS22-OT3-23-01
Published: 01 March 2023
View articletitled, Abstract OT3-23-01: VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
Journal Articles

Deregulation of SPOP in Cancer

Hui Zhang, Xiaofeng Jin, Haojie Huang
Journal: Cancer Research
Cancer Res (2023) 83 (4): 489–499.
https://doi.org/10.1158/0008-5472.CAN-22-2801
Published: 15 February 2023
View articletitled, Deregulation of SPOP in Cancer
Open the PDF for Deregulation of SPOP in Cancer in another window
Includes: Supplementary data
Journal Articles

Dopamine Signaling Promotes Tissue-Resident Memory Differentiation of CD8+ T Cells and Antitumor Immunity

Yingshi Chen, Shu-Mei Yan, Zeyu Pu, Jinzhu Feng, Likai Tan, Yuzhuang Li, Hongrong Hu, Wenjing Huang, Yingtong Lin, Zhilin Peng, Xin He, Feng Huang, Hui Zhang, Yiwen Zhang
Journal: Cancer Research
Cancer Res (2022) 82 (17): 3130–3142.
https://doi.org/10.1158/0008-5472.CAN-21-4084
Published: 02 September 2022
View articletitled, Dopamine Signaling Promotes Tissue-Resident Memory Differentiation of CD8+ T Cells and Antitumor Immunity
Open the PDF for Dopamine Signaling Promotes Tissue-Resident Memory Differentiation of CD8+ T Cells and Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

Abstract 1000: E-cadherin and EGFR interactions result in hyper-proliferation via ERK signaling in breast cancer

Gabriella C. Russo, Ashleigh Crawford, David J. Clark, Julie Cui, Ryan Carney, Michelle N. Karl, Boyang Su, Batrholomew Starich, Tung-Shing Lee, Qiming Zhang, Pei-hsun Wu, Meng-Horng Lee, Hon S. Leong, Vito Rebecca, Hui Zhang, Denis Wirtz
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1000.
https://doi.org/10.1158/1538-7445.AM2022-1000
Published: 15 June 2022
View articletitled, Abstract 1000: E-cadherin and EGFR interactions result in hyper-proliferation via ERK signaling in breast cancer
Journal Articles

Abstract 5873: Distinct prevalence and spectrum of germline cancer susceptibility gene mutations between early-onset and late-onset colorectal caner

Zhidong Gao, Jing Zhou, Ying Xin, Bin Liang, Kai Shen, Peng Guo, Kewei Jiang, Mujun Yin, Xiaodong Yang, Zhanlong Shen, Hui Zhang, Depei Huang, Yingjiang Ye
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5873.
https://doi.org/10.1158/1538-7445.AM2022-5873
Published: 15 June 2022
View articletitled, Abstract 5873: Distinct prevalence and spectrum of germline cancer susceptibility gene mutations between early-onset and late-onset colorectal caner
Journal Articles

Abstract 5193: Case report: Long-term response to Camrelizumab in a pretreated metastatic mixed testicular germ cell tumor patient

Hui Zhang, Da Jiang, Erhong Meng, Wenya Song, Xue Zhang
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 5193.
https://doi.org/10.1158/1538-7445.AM2022-5193
Published: 15 June 2022
View articletitled, Abstract 5193: Case report: Long-term response to Camrelizumab in a pretreated metastatic mixed testicular germ cell tumor patient